These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

795 related articles for article (PubMed ID: 14583994)

  • 21. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease.
    Kew KM; Seniukovich A
    Cochrane Database Syst Rev; 2014 Mar; 2014(3):CD010115. PubMed ID: 24615270
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial.
    Dalby C; Polanowski T; Larsson T; Borgström L; Edsbäcker S; Harrison TW
    Respir Res; 2009 Oct; 10(1):104. PubMed ID: 19878590
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease.
    Farne HA; Cates CJ
    Cochrane Database Syst Rev; 2015 Oct; (10):CD008989. PubMed ID: 26490945
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ipratropium bromide versus long-acting beta-2 agonists for stable chronic obstructive pulmonary disease.
    Appleton S; Jones T; Poole P; Pilotto L; Adams R; Lasserson TJ; Smith B; Muhammad J
    Cochrane Database Syst Rev; 2006 Jul; 2006(3):CD006101. PubMed ID: 16856113
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children.
    Lasserson TJ; Cates CJ; Ferrara G; Casali L
    Cochrane Database Syst Rev; 2008 Jul; (3):CD004106. PubMed ID: 18646100
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment comparison of budesonide/formoterol with salmeterol/fluticasone propionate in adults aged > or =16 years with asthma: post hoc analysis of a randomized, double-blind study.
    Kuna P
    Clin Drug Investig; 2010; 30(9):565-79. PubMed ID: 20593912
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety of regular formoterol or salmeterol in adults with asthma: an overview of Cochrane reviews.
    Cates CJ; Wieland LS; Oleszczuk M; Kew KM
    Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD010314. PubMed ID: 24504983
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events.
    Cates CJ; Lasserson TJ
    Sao Paulo Med J; 2010; 128(5):310-1. PubMed ID: 21181075
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chronic obstructive pulmonary disease: Useful medications for patients with recurrent symptoms.
    Prescrire Int; 2016 Nov; 25(176):272-277. PubMed ID: 30715829
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): Effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence.
    Blais L; Forget A; Ramachandran S
    Clin Ther; 2010 Jul; 32(7):1320-8. PubMed ID: 20678680
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease.
    Chong J; Karner C; Poole P
    Cochrane Database Syst Rev; 2012 Sep; 2012(9):CD009157. PubMed ID: 22972134
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Budesonide/formoterol vs. salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials.
    Halpin DM; Gray J; Edwards SJ; Morais J; Singh D
    Int J Clin Pract; 2011 Jul; 65(7):764-74. PubMed ID: 21676119
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhaled long acting beta agonists for stable chronic asthma.
    Walters EH; Walters JA; Gibson MD
    Cochrane Database Syst Rev; 2003; (4):CD001385. PubMed ID: 14583933
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-acting beta(2)-agonist in addition to tiotropium versus either tiotropium or long-acting beta(2)-agonist alone for chronic obstructive pulmonary disease.
    Karner C; Cates CJ
    Cochrane Database Syst Rev; 2012 Apr; 4(4):CD008989. PubMed ID: 22513969
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-acting beta2-agonists for chronic obstructive pulmonary disease.
    Appleton S; Smith B; Veale A; Bara A
    Cochrane Database Syst Rev; 2000; (2):CD001104. PubMed ID: 10796594
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting β2 agonist: observational matched cohort study (PATHOS).
    Janson C; Larsson K; Lisspers KH; Ställberg B; Stratelis G; Goike H; Jörgensen L; Johansson G
    BMJ; 2013 May; 346():f3306. PubMed ID: 23719639
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparing a fixed combination of budesonide/formoterol with other inhaled corticosteroid plus long-acting beta-agonist combinations in patients with chronic obstructive pulmonary disease: a review.
    Solidoro P; Patrucco F; Bagnasco D
    Expert Rev Respir Med; 2019 Nov; 13(11):1087-1094. PubMed ID: 31498714
    [No Abstract]   [Full Text] [Related]  

  • 38. A retrospective database study comparing treatment outcomes and cost associated with choice of fixed-dose inhaled corticosteroid/long-acting beta-agonists for asthma maintenance treatment in Germany.
    Aballéa S; Cure S; Vogelmeier C; Wirén A
    Int J Clin Pract; 2008 Dec; 62(12):1870-9. PubMed ID: 18803555
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Canadian economic evaluation of budesonide-formoterol as maintenance and reliever treatment in patients with moderate to severe asthma.
    Miller E; Sears MR; McIvor A; Liovas A
    Can Respir J; 2007; 14(5):269-75. PubMed ID: 17703241
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease.
    Spencer M; Briggs AH; Grossman RF; Rance L
    Pharmacoeconomics; 2005; 23(6):619-37. PubMed ID: 15960557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.